Tanguy Seiwert, MD, assistant professor of medicine and associate leader of the head and neck cancer program, University of Chicago, discusses the efficacy of pembrolizumab in head and neck cancer.

Seiwert discusses a recent expansion cohort of 135 patients with recurrent metastatic head and neck cancer treated with pembrolizumab as a single agent. Patients had a poor prognosis and were heavily pretreated.

Results showed that pembrolizumab achieved response in 25% of patients. While this is early data, Seiwert explains it is promising for treatment of the disease. Few patients, he adds, had severe adverse events.

View more from the 2015 ASCO Annual Meeting

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Immuno-Oncology

Head & Neck Cancers

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer. 

Dr. Seiwert on Pembrolizumab in Head and Neck Cancer